Insmed (NASDAQ:INSM – Get Free Report)‘s stock had its “buy” rating restated by analysts at Truist Financial in a report issued on Thursday, Benzinga reports. They presently have a $48.00 price target on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 92.38% from the company’s previous close. A number of […]
Insmed (NASDAQ:INSM – Free Report) had its price objective raised by The Goldman Sachs Group from $40.00 to $49.00 in a research note released on Wednesday, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other analysts have also issued reports on INSM. Wells Fargo & Company […]
Insmed Incorporated (NASDAQ:INSM) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Insmed Incorporated (NASDAQ:INSM) Receives Consensus Recommendation of Buy from Analysts themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Insmed Incorporated (NASDAQ:INSM) Q4 2023 Earnings Call Transcript February 22, 2024 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.28 EPS, expectations were $-1.13. Insmed Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to […]